Serum levels of macrophage inflammatory protein‐1 alpha (MIP‐1α) correlate with the extent of bone disease and survival in patients with multiple myeloma

This publication has 9 references indexed in Scilit:

• Tartrate‐resistant acid phosphatase isoform 5b: A novel serum marker for monitoring bone disease in multiple myeloma
  International Journal of Cancer, 2003
• Macrophage inflammatory protein 1-alpha (MIP-1α) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells
  Blood, 2003
• Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre‐treatment levels of S‐ICTP and U‐Ntx are predictive for early progression of the bone disease during standard chemotherapy
  British Journal of Haematology, 2003
• Receptor activator of NF-?B ligand, macrophage inflammatory protein-1?, and the proteasome
  Cancer, 2003
• Macrophage inflammatory protein‐1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM
  British Journal of Haematology, 2002
• Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma
  Blood, 2002
• Antisense inhibition of macrophage inflammatory protein 1-α blocks bone destruction in a model of myeloma bone disease
  Journal of Clinical Investigation, 2001
• Macrophage inflammatory protein-1α is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor κB ligand
  Blood, 2001
• Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma
  Blood, 2000